BioMarin Pharmaceutical Management
Management criteria checks 2/4
BioMarin Pharmaceutical's CEO is Alexander Hardy, appointed in Dec 2023, has a tenure of 1.25 years. total yearly compensation is $18.59M, comprised of 0.3% salary and 99.7% bonuses, including company stock and options. directly owns 0.034% of the company’s shares, worth $4.56M. The average tenure of the management team and the board of directors is 2 years and 4.9 years respectively.
Key information
Alexander Hardy
Chief executive officer
US$18.6m
Total compensation
| CEO salary percentage | 0.3% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.03% |
| Management average tenure | 2yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
The Strong Earnings Posted By BioMarin Pharmaceutical (NASDAQ:BMRN) Are A Good Indication Of The Strength Of The Business
Mar 04
BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Feb 21BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy
Jan 23Does BioMarin Pharmaceutical (NASDAQ:BMRN) Have A Healthy Balance Sheet?
Dec 26Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call
Nov 21BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Not Flying Under The Radar
Nov 14BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly
Sep 21BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
Aug 21BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
Jul 24An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued
Jun 01BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
May 15Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Apr 26BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business
Apr 21Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth
Feb 29BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?
Jan 19BioMarin redesigns organization, will lay off about 4% of its workforce
Oct 07BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy
Sep 29BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A
Sep 15CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | US$427m |
| Sep 30 2024 | n/a | n/a | US$322m |
| Jun 30 2024 | n/a | n/a | US$257m |
| Mar 31 2024 | n/a | n/a | US$205m |
| Dec 31 2023 | US$19m | US$65k | US$168m |
Compensation vs Market: Alexander's total compensation ($USD18.59M) is above average for companies of similar size in the US market ($USD13.21M).
Compensation vs Earnings: Insufficient data to compare Alexander's compensation with company performance.
CEO
Alexander Hardy (55 yo)
1.3yrs
Tenure
US$18,586,001
Compensation
Mr. Alexander Hardy serves as President, Chief Executive Officer & Director of BioMarin Pharmaceutical Inc. since December 01, 2023. He had been Chief Executive Officer at Genentech, Inc. since March 1, 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.3yrs | US$18.59m | 0.034% $ 4.6m | |
| Executive VP of Finance & CFO | 5.2yrs | US$4.85m | 0.052% $ 7.1m | |
| Executive VP & CTO | no data | US$5.70m | 0.032% $ 4.3m | |
| Group VP & Chief Accounting Officer | 2.8yrs | no data | 0.0096% $ 1.3m | |
| Chief Scientific Officer & Senior VP of Research and Early Development | no data | no data | no data | |
| Executive VP | 21.2yrs | US$5.19m | 0.043% $ 5.9m | |
| Executive VP & Chief People Officer | 6.2yrs | no data | no data | |
| Senior Vice President of Technical Development | 3.4yrs | no data | no data | |
| Executive VP & Chief Corporate Affairs Officer | 1.2yrs | no data | no data | |
| Executive VP & Chief Commercial Officer | less than a year | no data | no data | |
| Executive VP and Chief Research & Development Officer | less than a year | no data | no data | |
| Executive VP & Chief Business Officer | less than a year | no data | no data |
2.0yrs
Average Tenure
54yo
Average Age
Experienced Management: BMRN's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.3yrs | US$18.59m | 0.034% $ 4.6m | |
| Independent Chairman of the Board | 18.3yrs | US$515.44k | 0.060% $ 8.1m | |
| Independent Director | 9.2yrs | US$470.44k | 0.021% $ 2.9m | |
| Independent Director | 1.3yrs | US$213.38k | no data | |
| Independent Director | 22.7yrs | US$486.44k | 0.049% $ 6.6m | |
| Independent Director | 8.7yrs | US$480.44k | 0.012% $ 1.7m | |
| Director | less than a year | no data | 0.00022% $ 29.9k | |
| Independent Director | 4.1yrs | US$473.94k | 0.0065% $ 887.5k | |
| Independent Director | 7.5yrs | US$486.94k | 0.014% $ 1.9m | |
| Independent Director | 1.3yrs | US$213.38k | no data | |
| Independent Director | 5.7yrs | US$480.44k | 0.0099% $ 1.3m | |
| Independent Director | 1.3yrs | US$213.38k | no data |
4.9yrs
Average Tenure
62yo
Average Age
Experienced Board: BMRN's board of directors are considered experienced (4.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 02:38 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioMarin Pharmaceutical Inc. is covered by 55 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Ishan Majumdar | Baptista Research |
| Ying Huang | Barclays |